Published: Сб, Февраля 18, 2017
World | By Tasha Manning

Allergan recommits to NJ with plans for new, larger U.S. headquarters | FiercePharma

Allergan recommits to NJ with plans for new, larger U.S. headquarters | FiercePharma

Allergan may eschew the Big Pharma label, but it's moving into Big Pharma office building. The company is consolidating four of its locations in one big campus in Madison, NJ-a property that used to house Pfizer.

The company had been weighing US headquarters move to Lansdale, PA, but decided to double Down in New Jersey instead. Allergan will combine its US HQ, now in Parsippany, with three other operations scattered among three different New Jersey towns.

By keeping more than 1,000 jobs in the state, promising to add 300 more, and pledging $ 103 million In local investment, Allergan won $ 58 million in state incentives for the project.

This is not the first time Allergan has committed to New Jersey despite other alternatives. The company has not been based in New Jersey since 2013, when it bought Ireland's Warner Chilcott to move its domicile to that tax-friendly jurisdiction. Then known as Actavis, the company transferred its "headquarters" to Dublin, but kept its operations centered in the US

"Everybody loves New Jersey too much, so nobody is willing to go," then CEO Paul Bisaro said when analysts asked whether he'd be relocating, too. "There will be no management relocation."

Читайте также: KAYRO - One Kool Dude's Web Page

Allergan will revamp its future home base over the next year, planning to move in by the end of 2017. Formerly known as 5 Giralda Farms, the 463,000-

The state figures that the Allergan project will deliver $ 385 million in economic value to the state over the next 20 years. "Allergan is a significant employer in New Jersey, and its presence adds to the state's leadership in the pharmaceutical sector," according to NJ Economic Development Authority CEO Melissa Orsen.

The pharma business has long been a staple of the New Jersey economy, and it remains even after cutbacks and consolidations have drained away vacant jobs.

Roche ($ RHHBY) ditched its Nutley Campus last year, opting instead to cross the river into New York, while Novartis handed more than 365,000 square feet of leased office space in Florham Park. Others have relocated R & D to hot markets like Boston and San Francisco, hoping to tap R & D collaborations, academic centers and scads of biotech activity in those areas.

More recently, the Japanese drugmaker Daiichi Sankyo laid Off more than 1,000 staffers in the area, but chose to remain in New Jersey by consolidating R & D and commercial functions in Basking Ridge. The troubled drugmaker Valeant doubled the size of its New Jersey headquarters last year to combine operations previously housed elsewhere.

- see the NJEDA release

При любом использовании материалов сайта и дочерних проектов, гиперссылка на обязательна.
«» 2007 - 2017 Copyright.
Автоматизированное извлечение информации сайта запрещено.

Код для вставки в блог

Like this: